SS
CGEM icon

Steve Schonfeld’s Cullinan Oncology CGEM Stock Holding History

Steve Schonfeld’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,638
Closed -$172K – 2280
2025
Q4 		$172K Buy
+16,638
New +$150K ﹤0.01% 1743
2024
Q2 		– Sell
-60,074
Closed -$1.02M – 2200
2024
Q1 		$1.02M Sell
60,074
-80,926
-57% -$1.25M 0.01% 1216
2023
Q4 		$1.44M Buy
141,000
+19,200
+16% +$170K 0.01% 918
2023
Q3 		$1.1M Buy
121,800
+16,700
+16% +$174K 0.01% 990
2023
Q2 		$1.13M Buy
105,100
+70,700
+206% +$751K 0.01% 932
2023
Q1 		$352K Buy
34,400
+400
+1% +$4.41K ﹤0.01% 1305
2022
Q4 		$359K Buy
+34,000
New +$413K ﹤0.01% 1711
2021
Q4 		– Sell
-35,858
Closed -$809K – 2181
2021
Q3 		$809K Buy
+35,858
New +$959K 0.01% 1044
2021
Q2 		– Sell
-48,373
Closed -$2.02M – 1983
2021
Q1 		$2.02M Buy
+48,373
New +$1.96M 0.02% 657

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Steve Schonfeld's CGEM Position: Q1 2026 in Review

Steve Schonfeld sold out of Cullinan Oncology (CGEM) in Q1 2026, closing a stake of 16,638 shares — an estimated $172K sold.

Steve Schonfeld first reported a position in CGEM in Q1 2021 and held it in 9 quarters. The position peaked at $2.02M in Q1 2021. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Steve Schonfeld reported no remaining Cullinan Oncology position as of Q1 2026 after selling out during the quarter.
  • Steve Schonfeld sold 16,638 Cullinan Oncology shares in Q1 2026, an estimated $172K.
  • Steve Schonfeld first reported a position in Cullinan Oncology in Q1 2021 and held it in 9 quarters.
  • Steve Schonfeld's Cullinan Oncology position peaked at $2.02M in Q1 2021.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.